<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684056</url>
  </required_header>
  <id_info>
    <org_study_id>2020-YXKY-B010</org_study_id>
    <nct_id>NCT04684056</nct_id>
  </id_info>
  <brief_title>Laboratory Assessment of the Concentration of Direct Oral Anticoagulants in Patients With Atrial Fibrillation</brief_title>
  <acronym>LOAF</acronym>
  <official_title>Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants in Peri-operative Catheter Ablation for Patient With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan Asia General Hospital (http://wagh.com.cn)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan Asia Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of thromboembolic and bleeding event associated with catheter ablation for&#xD;
      atrial fibrillation(CAAF) varies from 0.9% to 5% during peri-operative period. Direct oral&#xD;
      anticoagulants (DOAC) (such as Rivaroxaban, Dabigatran and Edoxaban) are gradually applied in&#xD;
      clinical practice to prevent thrombosis events in patients with AF, but studies have shown&#xD;
      that DOAC are also affected by surgery, an invasive procedure, sub-therapeutic, food, renal&#xD;
      function and age. However, the pharmacokinetic and pharmacodynamic of DOAC during the&#xD;
      peri-operative period of CAAF were lacking in China. The purpose of this study was to&#xD;
      evaluate the pharmacokinetics and pharmacokinetics of DOAC in patients with peri-operative&#xD;
      atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of thromboembolic</measure>
    <time_frame>Ninety days after catheter ablation</time_frame>
    <description>Ischemic stroke, Deep vein thrombosis (DVT) or arterial thrombosis of any location after taking DOAC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding Incidence</measure>
    <time_frame>Ninety days after catheter ablation</time_frame>
    <description>Any bleeding, Especially gastrointestinal hemorrhage or hemoglobin drop is greater than 20g/L after taking DOAC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>Ninety days after catheter ablation</time_frame>
  </secondary_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">1864</enrollment>
  <condition>Oral Anticoagulant</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Pharmacokinetics and Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Riva-control group</arm_group_label>
    <description>Routine concentration of Rivaroxaban (Peak)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riva-High group</arm_group_label>
    <description>High concentration of Rivaroxaban (Peak)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riva-Low group</arm_group_label>
    <description>low concentration of Rivaroxaban (Peak)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabi-control group</arm_group_label>
    <description>Routine concentration of Dabigatran(Peak)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabi-High group</arm_group_label>
    <description>High concentration of Dabigatran(Peak)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabi-low group</arm_group_label>
    <description>low concentration of Dabigatran(Peak)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Edo-control group</arm_group_label>
    <description>Routine concentration of Edoxaban(Peak)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Edo-high group</arm_group_label>
    <description>High concentration of Edoxaban(Peak)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Edo-low group</arm_group_label>
    <description>low concentration of Edoxaban(Peak)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Catheter ablation was performed under general anesthesia in patients with NVAF. Direct oral&#xD;
        anticoagulants (Rivaroxaban, Edoxaban or Dabigatran )were administered peri-operatively to&#xD;
        prevent thrombotic events.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Non-valvular atrial fibrillation(NVAF) undergoing catheter ablation&#xD;
&#xD;
          -  Direct oral anticoagulants (Rivaroxaban, Edoxaban or Dabigatran)are administered&#xD;
             peri-operatively during catheter ablation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have taken direct oral anticoagulants or warfarin before admission.&#xD;
&#xD;
          -  Cross-replacement of oral anticoagulants, such as taking dabigatran before surgery and&#xD;
             replacing Rivaroxaban after surgery.&#xD;
&#xD;
          -  Abnormal coagulation tests (prothrombin time, partial thrombin time, thrombin time,&#xD;
             antithrombin activity).&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qingkun Fan, M.D</last_name>
    <phone>86+027-65796640</phone>
    <email>fqk@wahh.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Litao Zhang, M.D</last_name>
    <phone>86+027-65796640</phone>
    <email>zhangleetau@163.com</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Direct oral anticoagulants</keyword>
  <keyword>pharmacokinetics and pharmacodynamics</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Edoxaban</keyword>
  <keyword>Anti-FXa assays</keyword>
  <keyword>Dilute thrombin time</keyword>
  <keyword>Liquid-chromatography tandem mass spectrometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

